B48.2 Allescheriasis

Name of the Condition

• Allescheriasis

Summary

Allescheriasis is a rare fungal infection caused by Allescheria boydii (now classified as Scedosporium apiospermum), primarily affecting the lungs or skin. The condition may present as a localized or systemic infection, with manifestations ranging from asymptomatic colonization to severe invasive disease. It is often associated with environmental exposure and may occur in immunocompetent or immunocompromised individuals.

Causes

The infection is caused by Allescheria boydii (or Scedosporium apiospermum), a saprophytic fungus found in soil, decaying organic matter, and contaminated water. Transmission typically occurs through inhalation of fungal spores or direct inoculation of skin or mucous membranes. The organism can also spread hematogenously from a primary site to other organs.

Risk Factors

• Immunocompromised states, such as neutropenia, organ transplantation, or chronic steroid use.
• Prolonged exposure to soil or decaying organic matter.
• Underlying lung disease, including cystic fibrosis or bronchiectasis.
• Skin trauma or burns that facilitate fungal entry.
• Occupational or recreational activities involving contact with contaminated environments.

Symptoms

• Respiratory symptoms (e.g., cough, dyspnea, chest pain) in pulmonary cases.
• Skin lesions, such as nodules, ulcers, or abscesses, in cutaneous infections.
• Systemic symptoms (e.g., fever, malaise) in disseminated disease.
• Neurological symptoms (e.g., headache, seizures) if the central nervous system is involved.

Diagnosis

Diagnosis is confirmed by identifying the fungus in clinical specimens (e.g., sputum, tissue, or wound cultures) or histopathological examination. Imaging studies (e.g., chest X-ray or CT) may reveal characteristic findings, such as nodules or cavities in pulmonary cases. Molecular testing or fungal culture may be used to differentiate from similar pathogens.

Treatment Options

• Antifungal therapy, including voriconazole, posaconazole, or amphotericin B, guided by susceptibility testing.
• Surgical debridement or excision of localized lesions.
• Supportive care for systemic symptoms, such as oxygen therapy or management of organ dysfunction.
• Long-term suppressive therapy for immunocompromised patients to prevent recurrence.

Prognosis and Follow-Up

Prognosis varies depending on the site and severity of infection, as well as the patient’s immune status. Localized infections often respond well to treatment, while disseminated disease carries a higher risk of mortality. Follow-up includes monitoring for recurrence, especially in immunocompromised individuals, and repeat imaging or cultures if symptoms persist.

Complications

• Dissemination to other organs (e.g., brain, bones, or joints).
• Respiratory failure in severe pulmonary infections.
• Chronic skin ulcers or scarring.
• Treatment-related toxicity from antifungal medications.

Lifestyle & Prevention

• Avoid contact with soil or decaying organic matter, particularly in immunocompromised individuals.
• Use protective gear (e.g., gloves, masks) during activities with high exposure risk.
• Maintain good wound care to prevent fungal entry.
• Seek prompt medical evaluation for persistent respiratory or skin symptoms after environmental exposure.

When to Seek Professional Help

• Persistent cough, fever, or respiratory distress, especially after exposure to soil or contaminated water.
• Unexplained skin lesions, ulcers, or nodules that do not heal.
• Neurological symptoms (e.g., headache, confusion) in at-risk individuals.
• Worsening symptoms despite initial treatment or self-care measures.

Tips for Medical Coders

• Code B48.2 is specific to allescheriasis and should be used when the condition is documented. Ensure the diagnosis aligns with clinical findings and laboratory confirmation. Documentation should specify the site (e.g., pulmonary, cutaneous) and any associated complications to support accurate coding. Avoid using this code for other fungal infections or unspecified mycoses.